Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triprolidine + pseudoephedrine
- Development stage
- Unknown
- Lead developer
- LIFEPharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Coldifed is an orally administered combination medication developed and manufactured by LIFEPharma for the symptomatic relief of the common cold, cough, and allergic rhinitis. It contains two active small molecule ingredients: triprolidine hydrochloride and pseudoephedrine hydrochloride. Triprolidine is a first-generation antihistamine that functions as a selective antagonist of the histamine H1 receptor, reducing symptoms like sneezing and rhinorrhea. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, leading to vasoconstriction and reduced nasal congestion. The product is approved for marketing and is available in various formulations, including tablets and syrups, primarily in the Middle East region.
- Brand names
- Coldifed
- Other names
- triprolidine hydrochloride + pseudoephedrine hydrochloride
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)HTR7 (5-hydroxytryptamine receptor 7)mAChR (Muscarinic acetylcholine receptors)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on triprolidine + pseudoephedrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triprolidine + pseudoephedrine.